Health Economics›Mantle cell lymphoma›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Mantle cell lymphoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lenalidomide and Rituximab (R2) Variant #08	—	R 134 502	28d	—	~8.5 mo	~11	~R 396 684 PFS proxy · indirect	1
R-CODOX-M/R-IVAC Variant #05	—	R 127 189	—	—	—	~2	~R 254 379 PFS proxy · indirect	1
RiPAD+C Variant #01	—	R 87 063	35d	—	—	~6	~R 237 426 indirect	—
maxi-R-CHOP/R-HiDAC Variant #01	—	R 85 196	21d	—	—	~4	~R 177 874 indirect	—
BR/RC Variant #01	—	R 61 128	28d	—	—	~3	~R 183 383 indirect	—
R-BAC Variant #01	—	R 59 061	28d	—	—	~4	~R 132 625 indirect	—
Chlorambucil and Rituximab (RClb) Variant #01	—	R 52 650	42d	~23.1 mo	—	~6	~R 160 474 PFS proxy · indirect	3
Cladribine and Rituximab Variant #01	—	R 48 077	21d	—	—	~6	~R 288 462 indirect	—
R-HiDAC Variant #01	—	R 38 323	11d	—	—	~1	~R 38 323 indirect	—
Cladribine monotherapy Variant #03	—	R 34 921	35d	—	—	~1	~R 34 921 indirect	—
VcR-CVAD Variant #01	—	R 31 262	21d	—	—	~6	~R 187 569 indirect	—
R-DHAOx Variant #02	—	R 30 938	21d	—	—	~4	~R 123 751 indirect	—
R-DHAC Variant #01	—	R 30 694	21d	—	—	~4	~R 122 777 indirect	—
VR-CHOP Variant #01	—	R 30 327	21d	—	—	~6	~R 181 963 indirect	—
R-DHAP Variant #01	—	R 29 945	21d	—	~31.1 mo	~3	~R 89 835 PFS proxy · indirect	2
R-VAD+C Variant #01	—	R 29 145	35d	—	—	~8	~R 233 157 indirect	—
Rituximab monotherapy Variant #09 Partial	—	—	28d	~5.2 mo	—	~1	—	3
R-M-CHOP Partial	—	—	—	—	—	—	—	—
Watchful waiting Partial	—	—	—	~12.9 mo	—	—	—	—

19 of 19 regimens shown